Compulsory COVID and flu jabs being considered for England health staff
September 9, 2021Plans to make COVID-19 and flu vaccinations compulsory for frontline NHS staff in England are currently being discussed by the …
Rare nerve disorder listed as possible side effect of AZ’s COVID vaccine in EU
September 9, 2021An extremely rare nerve-damaging disorder, Guillain-Barré syndrome (GBS), has been listed by EU regulators as a possible side effect from …
Trials of former Theranos CEO Elizabeth Holmes are underway
September 8, 2021Medical Communications, Research and Development
The highly anticipated trials of Elizabeth Holmes, founder and former CEO of the now-defunct Theranos, have commenced. Prosecutors are to …
J&J’s prostate cancer drug recommended by NICE
September 8, 2021Research and Development
J&J have announced NICE are recommending apalutamide for treating prostate cancer following new draft guidance by the body. This is …
Amneal’s IPX-203 shows promising results for motor fluctuations in Parkinson’s disease
September 8, 2021Research and Development
Amneal Pharmaceuticals has recently announced that its product IPX-203 (carbidopa + levodopa, (CD/LD)) achieved key primary and secondary endpoints in …
COVID booster vaccines to get green light in “next few days”, according to health secretary
September 8, 2021Research and Development
Coronavirus booster jabs are expected to be approved in “the next few days”, the UK Health Secretary, Sajid David, has …
STI rates remain at concerning level despite 2020 fall
September 8, 2021Research and Development
New data from Public Health England (PHE) reveal that despite diagnoses of sexually transmitted infections (STIs) decreasing in 2020 by …
Sanofi acquires Kadmon in $1.9 billion deal
September 8, 2021Research and Development
Sanofi has announced that is has entered into a definitive merger agreement with Kadmon Holdings adding Rezurock (belumosudil) to its …
Wider use of SGLT2 inhibitors for CVD recommended by NICE
September 7, 2021Manufacturing and Production, Medical Communications
NICE has updated its guidelines on the management of type 2 diabetes, recommending wider use of SGLT2 inhibitors in those …
FDA halts BioMarin’s PKU gene therapy trial
September 7, 2021Manufacturing and Production, Medical Communications, Research and Development
BioMarin Pharma has announced that the FDA has slapped a clinical hold on its Phase 1/2 trial of its candidate …
NHS to receive additional £5.4 billion for COVID-19 response
September 7, 2021Manufacturing and Production
The NHS will receive an extra £5.4 billion over the next six months to support its response to COVID-19 and …
Vaginal ring could help prevent HIV infection in women
September 7, 2021Manufacturing and Production, Research and Development
Researchers from the Kenya Medical Research Institute (KEMRI) are exploring the use of an intra vaginal ring containing anti-HIV medication …
“Highly effective” rheumatoid arthritis treatment possible after breakthrough
September 7, 2021Manufacturing and Production
A “highly effective” treatment for rheumatoid arthritis could be made available in several years after scientists have uncovered a new …
Sinovac booster jab reverses antibody drop from Delta variant, study finds
September 6, 2021Medical Communications, Research and Development, Sales and Marketing
Researchers have found that a booster shot of Sinovac’s COVID-19 vaccine reverses a decline in antibody activities against the Delta …
Israel to present COVID booster-shot data to FDA
September 6, 2021Sales and Marketing
This month Israel will present COVID booster-shot data to the FDA, which is weighing White House plans to begin a …
COVID vaccine passports to start in England this month
September 6, 2021Medical Communications, Sales and Marketing
The Vaccine Minister, Nadhim Zahawi, has confirmed that vaccine passports will be required in nightclubs and other indoor venues at …
Bimekizumab receives first positive health technology assessment worldwide
September 6, 2021Sales and Marketing
NICE has published its final Technology Appraisal Guidance (TAG) recommending UCB’s BIMZELX (bimekizumab) as a treatment option for adults with …
Newron begins first potentially pivotal schizophrenia study
September 6, 2021Sales and Marketing
Newron has initiated Study 008A, the first potentially pivotal study with evenamide in patients with schizophrenia.Study 008A, a four-week, randomised, …
WHO: Number of dementia sufferers to rise 40% to 78 million by 2030
September 3, 2021Medical Communications
A new report from the WHO has predicted the number of people suffering from dementia is set to rise by …
NICE approves secukinumab for young people with severe plaque psoriasis
September 3, 2021Medical Communications
NICE has approved secukinumab (Cosentyx) as an option for treating moderate to severe plaque psoriasis in people aged six to …
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
